👀 Ones to watch: Undervalued stocks to buy before they report Q3 earningsSee Undervalued Stocks

Capricor Therapeutics Inc (CAPR)

NASDAQ
Currency in USD
Disclaimer
19.580
+1.810(+10.19%)
Closed
After Hours
19.530-0.050(-0.255%)
CAPR Scorecard
Full Analysis
2 analysts have revised their earnings downwards for the upcoming period
Fair Value
Day's Range
17.02019.790
52 wk Range
2.68021.980
Prev. Close
17.77
Open
17.78
Day's Range
17.02-19.79
52 wk Range
2.68-21.98
Volume
2,091,299
Average Volume (3m)
2,619,941
1-Year Change
584.62%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
CAPR Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
41.800
Upside
+113.483%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory
Show more

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company’s lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.

Compare CAPR to Peers and Sector

Metrics to compare
CAPR
Peers
Sector
Relationship
P/E Ratio
−24.8x−0.6x−0.6x
PEG Ratio
−1.240.000.00
Price/Book
60.2x0.5x2.6x
Price / LTM Sales
25.5x10.2x3.2x
Upside (Analyst Target)
99.2%602.5%47.1%
Fair Value Upside
Unlock26.3%7.1%Unlock

FAQ

What Is the Capricor Therapeutics (CAPR) Stock Price Today?

The Capricor Therapeutics stock price today is 19.58.

What Stock Exchange Does Capricor Therapeutics Trade On?

Capricor Therapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Capricor Therapeutics?

The stock symbol for Capricor Therapeutics is "CAPR."

What Is the Capricor Therapeutics Market Cap?

As of today, Capricor Therapeutics market cap is 689.08M.

What is Capricor Therapeutics Earnings Per Share?

The Capricor Therapeutics EPS is -0.934.

What Is the Next Capricor Therapeutics Earnings Date?

Capricor Therapeutics will release its next earnings report on 06 Nov 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.